More and more individuals now have chronically implanted brain-computer interface (BCI) systems in their heads. Devices that can record and stimulate neural signals are...

MPM Bioimpact-spawned K2 Therapeutics Inc. inked a license deal plus option agreement, worth $980.5 million apiece, to gain ex-China rights to two of Antengene Corp. Ltd.’s...

In a little more than a month, 17 big biopharma companies will be subject to U.S. President Donald Trump’s long-promised section 232 global biopharma sector tariff. But...

China’s National Medical Products Administration has approved Suzhou Alphamab Co. Ltd.’s HER2 bispecific antibody, anbenitamab (KN-026), through priority review for adults...